Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET

Company Participants

Todd Friedman - Director, Investor Relations

Christian Henry - President & Chief Executive Officer

Susan Kim - Chief Financial Officer

Conference Call Participants

Kyle Mikson - Canaccord

Julia Qin - JPMorgan

Tejas Savant - Morgan Stanley

Dan Brennan - Cowen

David Westenberg - Piper Sandler

Sung Ji Nam - Scotiabank

John Sourbeer - UBS

Ross Osborn - Cantor Fitzgerald

Operator

Hello, and welcome to the PacBio Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. [Operator instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Todd Friedman, Director of Investor Relations. Todd, please go ahead.

Todd Friedman

Good afternoon, and welcome to PacBio’s fourth quarter 2022 earnings conference call. Earlier today, we issued a press release outlining the financial results we will be discussing on today’s call, a copy of which is on the Investor section of our website, www.pacb.com, or as furnished on Form 8-K available on the Securities and Exchange Commission website at www.sec.gov.

With me today are Christian Henry, President and Chief Executive Officer; and Susan Kim, Chief Financial Officer.

Before we begin, I would like to remind you that on today’s call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, intentions, guidance, and others, including expectations regarding our Revio Onso system in their commercialization timeframe, the future availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using PacBio products or technology, including our Revio Onso systems.

You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed, including those inherent in developing and commercializing new products.

We refer you to the documents that we file with the SEC, including our most recent forms 10-Q and 10-K and our recent press release to better understand the risks and uncertainties that could cause actual results to differ. We disclaim any obligation to update or revise these forward-looking statements except as required by law.

During the call, we will also present certain financial information on a non-GAAP basis. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement and understanding of the company's operating results as reported under US GAAP. Management believes that non-GAAP financial measures, combined with US GAAP financial measures, provide useful information to compare our performance relative to forecasts and strategic plans and benchmark our performance externally against competitors.